Directorate Changes

RNS Number : 1614N
Venture Life Group PLC
30 May 2022

30th May 2022



("Venture Life" "VLG" or the "Group")

Directorate Changes


Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces that Mr Peter Bream, non-executive Director and Chair of the Audit Committee, after serving on the Board for seven years, has given the Company notice of his resignation in order to facilitate Director rotation in line with good corporate governance.

The Company also announces that Mr Carl Dempsey, non-executive Director and Chair of the Remuneration Committee will also be stepping down. Mr Dempsey has served on the Board of the Company for three years, but has decided that, due to the workload required from his other business interests, and accelerating new ventures, he is unable to continue to dedicate the required time to his position on the Board of Venture Life.

A search process has begun to replace both Mr Bream and Mr Dempsey, and they will both continue to serve on the Board of the Company until their replacements are appointed.


Jerry Randall, CEO of Venture Life commented: " I would like to extend my thanks to both Peter and Carl on behalf of myself and the whole team of Venture Life for all of their advice, support and input to the business over the time they have been with us. The business has grown significantly over their time with us, and in the last few years managed its way through significant challenges that the global markets have experienced. I wish both Peter and Carl the very best for their future endeavours."

Paul McGreevy, non-executive Chair of Venture Life commented: " It's clearly evident that both Peter and Carl's contribution to the business has been significant in our governance, compliance and growth, and have helped build a sustainable platform from which we can accelerate our ambitions. I'd like to thank them both for their professionalism and support given to Venture Life."



For further information, please contact:


Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer


Cenkos Securities plc (Nomad and Joint Broker)


+44 (0) 20 7397 8900

Michael Johnson/Russell Kerr (Sales)

Stephen Keys/Camilla Hume (Corporate Finance)



Singer Capital markets (Joint Broker)


+44 (0) 20 7496 3000

Jonathan Dighe (Sales)

Shaun Dobson/Alaina Wong (Corporate Finance)



About Venture Life ( )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100